Shire (SHPG) Earns Media Impact Score of 0.18
Press coverage about Shire (NASDAQ:SHPG) has been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a news impact score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.3486589802126 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Shire (SHPG) a Sell on Sagging Quant Score (investorplace.com)
- Shire plc (NASDAQ:SHPG) – Lower The P/E, the Higher The Value of The Stock Justification – Nasdaq Journal (press release) (nasdaqjournal.com)
- Notable Stocks Roundup: Shire plc, (NASDAQ: SHPG), Intercept Pharmaceuticals, Inc., (NASDAQ: ICPT), Haemonetics … – Stocks In The News (press release) (tradingnewsnow.com)
- Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill™ Technology for the Oral Delivery of Factor Therapy (pharmiweb.com)
- Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology (finance.yahoo.com)
A number of equities research analysts have weighed in on the stock. Evercore ISI assumed coverage on shares of Shire in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price objective on the stock. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 price objective on shares of Shire in a report on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Shire in a report on Sunday, October 8th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Tuesday, December 5th. Finally, Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $212.18.
Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion for the quarter. During the same quarter in the previous year, the company earned $3.17 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. sell-side analysts forecast that Shire will post 15 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/11/shire-shpg-earns-media-impact-score-of-0-18.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.